within Pharmacolibrary.Drugs.ATC.N;

model N02CC05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.0003383333333333334,
    adminDuration  = 600,
    adminMass      = 12.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006333333333333333,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02CC05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Almotriptan is a selective serotonin 5-HT1B/1D receptor agonist (triptan) used for the acute treatment of migraine attacks with or without aura in adults. It is approved and currently used in several countries for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, both male and female, following single oral administration of almotriptan.</p><h4>References</h4><ol><li><p>McEwen, J, et al., &amp; Cabarrocas, X (2004). Pharmacokinetics and safety of oral almotriptan in healthy male volunteers. <i>Biopharmaceutics &amp; drug disposition</i> 25(7) 303–311. DOI:<a href=&quot;https://doi.org/10.1002/bdd.412&quot;>10.1002/bdd.412</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15386481/&quot;>https://pubmed.ncbi.nlm.nih.gov/15386481</a></p></li><li><p>Dowson, AJ (2004). Oral almotriptan: practical uses in the acute treatment of migraine. <i>Expert review of neurotherapeutics</i> 4(3) 339–348. DOI:<a href=&quot;https://doi.org/10.1586/14737175.4.3.339&quot;>10.1586/14737175.4.3.339</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15853532/&quot;>https://pubmed.ncbi.nlm.nih.gov/15853532</a></p></li><li><p>McEnroe, JD, &amp; Fleishaker, JC (2005). Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. <i>Clinical pharmacokinetics</i> 44(3) 237–246. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200544030-00002&quot;>10.2165/00003088-200544030-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15762767/&quot;>https://pubmed.ncbi.nlm.nih.gov/15762767</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02CC05;
